In the PACMAN-AMI trial, the use of alirocumab in addition to high-intensity statin therapy resulted in a significant regression of percent atheroma volume in the two non-infarct-related coronary arteries and increased plaque stability in patients with acute myocardial infarction without a reduction of hs-CRP (14). Here, CRP is linked to myocardial infarction.